New Concepts in ADT- Thomas Keane

(Length of Discussion: 21 min)

Tom Keane brings new concepts in androgen deprivation therapy (ADT) to light specifically discussing agonists versus antagonists, new androgen receptor-targeted drugs, including immunotherapy biomarkers, and genomic testing. He reviews the current state of the CRPC treatment and ADT options for use in advanced metastatic disease and concludes with a discussion on treating earlier versus later disease. 


Thomas E. Keane, MBBCh, FRCSI, FACS

Related Content:

A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.

Watch: Navigating the Adverse Effects of ADT - Neal Shore

Watch: Bones, Hot Flashes and ADT: Using with Chemotherapy and Timing - Thomas Keane

Watch: ADT Impact on Cardiovascular Health - Jehonathan Pinthus


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.